3 Growth Companies With High Insider Ownership To Watch

As global markets continue their upward trajectory, driven by optimism surrounding AI advancements and a potential easing of trade tensions, growth stocks have notably outperformed value shares for the first time this year. In such an environment, companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)	17.3%	20.5%
Seojin SystemLtd (KOSDAQ:A178320)	32.1%	39.9%
SKS Technologies Group (ASX:SKS)	29.7%	24.8%
Propel Holdings (TSX:PRL)	36.5%	38.9%
On Holding (NYSE:ONON)	19.1%	29.7%
Pharma Mar (BME:PHM)	11.9%	55.1%
Kingstone Companies (NasdaqCM:KINS)	20.8%	24.9%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	135%
Elliptic Laboratories (OB:ELABS)	26.8%	121.1%
Fulin Precision (SZSE:300432)	13.6%	71%

Click here to see the full list of 1477 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

MedinCell (ENXTPA:MEDCL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MedinCell S.A. is a pharmaceutical company based in France that focuses on developing long-acting injectables across various therapeutic areas, with a market cap of €472.93 million.

Operations: The company's revenue is primarily generated from its Pharmaceuticals segment, amounting to €13.20 million.

Insider Ownership: 15.8%

MedinCell is positioned for robust growth, with revenue expected to increase by 63.8% annually, outpacing the French market's 5.5%. Although currently unprofitable with negative equity and a volatile share price, it trades at 79.4% below its estimated fair value. Analysts predict a potential stock price rise of 38.1%, and earnings are forecasted to grow by 114.27% annually, signaling strong future profitability despite recent net losses of €14.57 million for H1 2025.

• Take a closer look at MedinCell's potential here in our earnings growth report.
• According our valuation report, there's an indication that MedinCell's share price might be on the cheaper side.

Swedencare (OM:SECARE)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Swedencare AB (publ) develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses across Sweden, the United Kingdom, Europe, North America, Asia, and internationally with a market cap of SEK7.58 billion.

Operations: The company's revenue segments include SEK397.40 million from Europe, SEK659 million from Production, and SEK1.66 billion from North America.

Insider Ownership: 12.2%

Swedencare is poised for significant earnings growth, forecasted at 64.33% annually, surpassing the Swedish market's 13.9%. Despite revenue growth of 12.9% being below the desired threshold, it exceeds the market average. Trading at 66.9% below estimated fair value suggests potential undervaluation. Insider activity shows more buying than selling recently, indicating confidence in future prospects despite low projected return on equity and declining profit margins from last year’s figures.

• Click here and access our complete growth analysis report to understand the dynamics of Swedencare.
• According our valuation report, there's an indication that Swedencare's share price might be on the expensive side.

LifeTech Scientific (SEHK:1302)

Simply Wall St Growth Rating: ★★★★★☆

Overview: LifeTech Scientific Corporation is an investment holding company that develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases globally, with a market cap of HK$6.02 billion.

Operations: The company generates revenue from its Structural Heart Diseases Business (CN¥523.01 million), Peripheral Vascular Diseases Business (CN¥725.13 million), and Cardiac Pacing and Electrophysiology Business (CN¥32.36 million).

Insider Ownership: 16%

LifeTech Scientific is positioned for substantial growth with earnings expected to rise 29.5% annually, outpacing the Hong Kong market's 11.2%. Revenue is forecasted to grow at 21.5% per year, significantly above the market average of 7.7%. Recent board changes include Ms. Ruan Xingmei's appointment as an executive director, bringing extensive financial expertise to the company. Despite lower profit margins this year and no recent insider trading activity, growth prospects remain strong.

• Click to explore a detailed breakdown of our findings in LifeTech Scientific's earnings growth report.
• Our valuation report unveils the possibility LifeTech Scientific's shares may be trading at a premium.

Key Takeaways

• Unlock our comprehensive list of 1477 Fast Growing Companies With High Insider Ownership by clicking here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com